Saudi Arabia Oral Solid Dosage Contract Manufacturing Market Report Size Share Growth Drivers Trends Opportunities & Forecast 2025–2030

Saudi Arabia Oral Solid Dosage Contract Manufacturing Market Overview

• The Saudi Arabia Oral Solid Dosage Contract Manufacturing Market is valued at USD 330 million, based on a five-year historical analysis of country-level oral solid dosage contract manufacturing revenues and their share within the broader pharmaceutical CDMO market in Saudi Arabia. This growth is primarily driven by the increasing demand for generic medications, rising healthcare expenditure under national health transformation initiatives, and the expansion of the domestic pharmaceutical manufacturing base. The market is also supported by the growing trend of outsourcing manufacturing processes by pharmaceutical and biotech companies to improve cost-efficiency, access specialized technologies for tablets and capsules, and accelerate time-to-market.
• Key cities dominating this market include Riyadh, Jeddah, and Dammam. Riyadh serves as the capital and a major economic hub, concentrating many leading local pharmaceutical manufacturers and CDMOs, as well as national-level healthcare institutions and procurement bodies. Jeddah, with its strategic Red Sea port, facilitates the import of raw materials and export of finished pharmaceutical products, supporting regional distribution of oral solid dosage forms. Dammam and the broader Eastern Province host several industrial and pharmaceutical manufacturing zones, enabling clustering of formulation plants and packaging facilities that are important for the oral solid dosage value chain.
• In 2023, the Saudi Food and Drug Authority (SFDA) continued to strengthen and operationalize regulations aimed at enhancing the quality and safety of pharmaceutical products, including those manufactured under contract. The SFDA’s Pharmaceutical Products Registration Guidelines and Good Manufacturing Practice (GMP) Regulations, issued under the authority of the Saudi Food and Drug Authority Law and enforced through the SFDA’s Drug Sector, require all manufacturers and contract manufacturers to obtain a manufacturing license, comply with SFDA GMP guidelines aligned with PIC/S and WHO standards, implement validated quality systems, and undergo periodic SFDA inspections as a condition for maintaining market authorization. These requirements have raised manufacturing and documentation standards for oral solid dosage forms, supporting higher product quality, batch traceability, and pharmacovigilance in the market.

Saudi Arabia Oral Solid Dosage Contract Manufacturing Market Segmentation

By Product Type:

The product type segmentation includes Tablets, Capsules, Powders, Granules, and Others (e.g., lozenges, pellets). Among these, Tablets dominate the market due to their widespread use, ease of administration, and suitability for high-volume chronic therapies such as cardiovascular and metabolic conditions. The preference for tablets is driven by their stability, accurate dose uniformity, scalability in manufacturing, and cost-effectiveness. Capsules are also gaining traction, particularly in the nutraceutical and specialty prescription segments, as they can accommodate complex, multiparticulate, or moisture-sensitive formulations and enable faster product lifecycle management. Powders and Granules are utilized for specific therapeutic applications, pediatric and geriatric patients, and as intermediates for further tableting or encapsulation. The Others category, which includes lozenges, pellets, and orally disintegrating forms, caters to niche patient-centric and fast-dissolving formulations, contributing to the overall diversification of product offerings.

By Release / Formulation Type:

This segmentation includes Immediate Release (IR), Extended / Controlled Release (CR), Delayed Release (DR) / Enteric-coated, Fixed-dose Combinations, and Others. The Immediate Release (IR) formulations lead the market due to their rapid onset of action and suitability for a broad range of acute and chronic indications, making them the most commonly outsourced oral dosage form globally and in the region. Extended and Controlled Release formulations are gaining popularity for chronic conditions such as diabetes, hypertension, and psychiatric disorders, as they enable sustained therapeutic levels, improved adherence, and reduced dosing frequency, which encourages originator and generic companies to partner with CDMOs that have advanced formulation capabilities. Delayed Release and enteric?coated formulations are utilized to protect acid?labile drugs, target specific intestinal regions, and reduce gastrointestinal side effects, requiring specialized coating technologies that CDMOs increasingly provide. Fixed-dose Combinations are favored for their convenience in managing comorbidities and aligning with national treatment guidelines, especially in cardiovascular and metabolic diseases, and they support differentiation in the generics space. The Others category includes orally disintegrating tablets, multi-layer tablets, and abuse-deterrent or modified-release technologies that cater to specific patient needs and align with the broader trend toward patient-centric drug delivery.

Saudi Arabia Oral Solid Dosage Contract Manufacturing Market Competitive Landscape

The Saudi Arabia Oral Solid Dosage Contract Manufacturing Market is characterized by a dynamic mix of regional and international players. Leading participants such as Saudi Pharmaceutical Industries and Medical Appliances Corporation (SPIMACO), Tabuk Pharmaceuticals Manufacturing Company, Jamjoom Pharma, Riyadh Pharma (Medical Application Company), Saudi Chemical Company Holding – AJA Pharma, Jamjoom Medical Industries, Sudair Pharma Company, Hikma Pharmaceuticals, Julphar Gulf Pharmaceutical Industries, Tabuk Pharmaceuticals Manufacturing Marketing Affiliates (Saudi), Pfizer Saudi Limited, Sanofi Saudi Arabia, Bayer Saudi Arabia, Merck Sharp & Dohme (MSD) Saudi Arabia, Other Emerging Saudi CDMOs contribute to innovation, geographic expansion, technology transfer, and service delivery in this space by investing in local manufacturing, quality upgrades, and broader portfolios of tablets and capsules for both branded and generic therapies.

Saudi Arabia Oral Solid Dosage Contract Manufacturing Market Industry Analysis

Growth Drivers

• Increasing Demand for Generic Medications:The Saudi Arabian market for generic medications is projected to reach SAR 12 billion in future, driven by a growing population and rising healthcare costs. The government’s push for affordable healthcare solutions has led to a 20% increase in generic drug prescriptions over the past two years. This trend is further supported by the World Health Organization's initiatives to promote generic drugs, enhancing their availability and affordability in the region.
• Expansion of Healthcare Infrastructure:Saudi Arabia's healthcare expenditure is expected to exceed SAR 250 billion in future, reflecting a 12% annual growth rate. This expansion includes the construction of new hospitals and clinics, which will increase the demand for oral solid dosage forms. The Vision 2030 initiative aims to improve healthcare access, thereby boosting the contract manufacturing sector as local firms seek to meet the rising demand for pharmaceuticals.
• Rising Prevalence of Chronic Diseases:Chronic diseases such as diabetes and cardiovascular conditions are on the rise, with the Saudi Ministry of Health reporting that 35% of the population is affected. This increase is expected to drive the demand for oral solid dosage forms, as these are commonly prescribed for chronic disease management. The market for chronic disease medications is projected to grow significantly, necessitating enhanced manufacturing capabilities to meet patient needs.

Market Challenges

• Stringent Regulatory Requirements:The Saudi Food and Drug Authority (SFDA) enforces strict regulations that can delay the approval of new drugs. In future, the average approval time for new drug applications is reported at 16 months, which can hinder market entry for contract manufacturers. Compliance with international standards adds complexity, requiring significant investment in quality assurance and regulatory affairs to navigate these challenges effectively.
• High Competition from Established Players:The oral solid dosage market in Saudi Arabia is dominated by established pharmaceutical companies, which hold approximately 75% of the market share. New entrants face significant barriers, including brand loyalty and established distribution networks. This competitive landscape necessitates innovative strategies and differentiation for contract manufacturers to capture market share and sustain profitability in a challenging environment.

Saudi Arabia Oral Solid Dosage Contract Manufacturing Market Future Outlook

The future of the Saudi Arabia oral solid dosage contract manufacturing market appears promising, driven by advancements in technology and increasing healthcare investments. As the government continues to support local manufacturing through incentives, companies are likely to adopt innovative production methods. Additionally, the growing focus on personalized medicine and biopharmaceuticals will create new avenues for growth, enabling manufacturers to cater to evolving patient needs and preferences in the coming years.

Market Opportunities

• Growth in Biopharmaceuticals:The biopharmaceutical sector in Saudi Arabia is projected to grow to SAR 6 billion in future, presenting significant opportunities for contract manufacturers. This growth is driven by increased investment in research and development, allowing manufacturers to diversify their product offerings and cater to the rising demand for biologics and biosimilars in the region.
• Technological Advancements in Manufacturing:The adoption of advanced manufacturing technologies, such as automation and artificial intelligence, is expected to enhance production efficiency. In future, it is estimated that 50% of manufacturing processes will be automated, reducing operational costs and improving product quality. This technological shift will enable contract manufacturers to meet the growing demand for high-quality oral solid dosage forms more effectively.